FindTrial
Sign In

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524905-34-00
Enrollment
63
Registered
2026-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Brief summary

Incidence of adverse events (AEs) including related AEs, AE leading to discontinuation, serious adverse events (SAEs) and deaths

Interventions

DRUGDEXAMETHASONE
DRUGPEMETREXED
DRUGAdagrasib
DRUGCETUXIMAB
DRUGPALONOSETRON
DRUGPEMBROLIZUMAB

Sponsors

Bristol-Myers Squibb Services Unlimited Company
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Incidence of adverse events (AEs) including related AEs, AE leading to discontinuation, serious adverse events (SAEs) and deaths—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 27, 2026